JP2012067116A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012067116A5 JP2012067116A5 JP2011246211A JP2011246211A JP2012067116A5 JP 2012067116 A5 JP2012067116 A5 JP 2012067116A5 JP 2011246211 A JP2011246211 A JP 2011246211A JP 2011246211 A JP2011246211 A JP 2011246211A JP 2012067116 A5 JP2012067116 A5 JP 2012067116A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- cancer
- composition according
- initial dose
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 9
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 239000005557 antagonist Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 230000004927 fusion Effects 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 claims 1
- 108700021154 Metallothionein 3 Proteins 0.000 claims 1
- 102100028708 Metallothionein-3 Human genes 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000003145 cytotoxic factor Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000013535 dynamic contrast enhanced MRI Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57849904P | 2004-06-10 | 2004-06-10 | |
| US60/578,499 | 2004-06-10 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527795A Division JP2008502738A (ja) | 2004-06-10 | 2005-06-10 | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012067116A JP2012067116A (ja) | 2012-04-05 |
| JP2012067116A5 true JP2012067116A5 (US20070167479A1-20070719-C00034.png) | 2013-11-07 |
Family
ID=35510259
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527795A Withdrawn JP2008502738A (ja) | 2004-06-10 | 2005-06-10 | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
| JP2011246211A Withdrawn JP2012067116A (ja) | 2004-06-10 | 2011-11-10 | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007527795A Withdrawn JP2008502738A (ja) | 2004-06-10 | 2005-06-10 | ヒトの癌を処置するための、ｖｅｇｆインヒビターの使用 |
Country Status (9)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06014689A (es) * | 2004-06-18 | 2008-03-11 | Regeneron Pharma | Inhibidores del vegf para el tratamiento de efusion pleural maligna. |
| PT1861116E (pt) | 2005-03-25 | 2015-11-04 | Regeneron Pharma | Formulações de antagonista do vegf |
| JP2009504679A (ja) | 2005-08-12 | 2009-02-05 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｖｅｇｆアンタゴニストを用いて疾患を処置する方法 |
| JP2009537606A (ja) * | 2006-05-25 | 2009-10-29 | ノバルティス アクチエンゲゼルシャフト | チロシンキナーゼ阻害剤 |
| CN101478949A (zh) | 2006-06-16 | 2009-07-08 | 瑞泽恩制药公司 | 适合玻璃体内施用的vegf拮抗剂的制剂 |
| GB0612721D0 (en) * | 2006-06-27 | 2006-08-09 | Novartis Ag | Organic compounds |
| BRPI0717431A2 (pt) | 2006-09-29 | 2013-11-12 | Oncomed Pharm Inc | Composições e métodos de diagnóstico e tratamento do câncer |
| AU2014201795B2 (en) * | 2006-12-19 | 2016-05-19 | Genentech, Inc. | VEGF-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| EP2101807B1 (en) * | 2006-12-19 | 2016-05-25 | Genentech, Inc. | Vegf-specific antagonists for adjuvant and neoadjuvant therapy and the treatment of early stage tumors |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| KR20160021308A (ko) * | 2008-12-23 | 2016-02-24 | 제넨테크, 인크. | 암 환자에서의 진단 목적용 방법 및 조성물 |
| CA3080983C (en) | 2009-05-27 | 2023-02-28 | Pct Therapeutics, Inc. | Method of inhibiting and reducing a viral infection |
| DK2488204T3 (en) | 2009-10-16 | 2016-06-06 | Oncomed Pharm Inc | Therapeutic combination and use of DLL4 antagonist antibodies and blood pressure lowering agents |
| WO2012010546A1 (en) * | 2010-07-19 | 2012-01-26 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
| US8551479B2 (en) | 2010-09-10 | 2013-10-08 | Oncomed Pharmaceuticals, Inc. | Methods for treating melanoma |
| KR20220097542A (ko) | 2011-01-13 | 2022-07-07 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| JO3283B1 (ar) | 2011-04-26 | 2018-09-16 | Sanofi Sa | تركيب يتضمن أفليبيرسيبت, حمض فولينيك, 5- فلورويوراسيل (5- Fu) وإرينوسيتان (FOLFIRI) |
| EP2546268A1 (en) | 2011-07-13 | 2013-01-16 | F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. | Internalising immunoglobulin |
| US8858941B2 (en) | 2011-09-23 | 2014-10-14 | Oncomed Pharmaceuticals, Inc. | VEGF/DLL4 binding agents and uses thereof |
| EP2914961A4 (en) | 2012-10-31 | 2016-04-20 | Oncomed Pharm Inc | METHODS AND MONITORING A TREATMENT BY AN ANTAGONIST OF DLL4 |
| CA2901226C (en) | 2013-02-18 | 2020-11-17 | Vegenics Pty Limited | Vascular endothelial growth factor binding proteins |
| AU2015208482B2 (en) * | 2014-01-25 | 2017-02-02 | Chengdu Kanghong Biotechnologies Co., Ltd. | Fusion protein inhibiting angiogenesis or growth and use thereof |
| CN104004058B (zh) * | 2014-06-23 | 2016-06-08 | 栾晓鹏 | 有关白介素-33抑制剂多肽及其应用 |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| EP3170005B1 (en) | 2014-07-18 | 2019-04-10 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer |
| US20160176962A1 (en) | 2014-10-31 | 2016-06-23 | Oncomed Pharmaceuticals, Inc. | Combination Therapy For Treatment Of Disease |
| JP2017535548A (ja) * | 2014-11-14 | 2017-11-30 | ジェネンテック， インコーポレイテッド | Ｖｅｇｆアンタゴニストの応答の予測 |
| US11339213B2 (en) | 2015-09-23 | 2022-05-24 | Mereo Biopharma 5, Inc. | Methods and compositions for treatment of cancer |
| IL290457B1 (en) | 2015-12-30 | 2024-10-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| CA3012060A1 (en) * | 2016-01-25 | 2017-08-03 | Sanofi | Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker |
| CA3014888A1 (en) | 2016-02-18 | 2017-08-24 | University Of Massachusetts | Combination therapy |
| KR101685532B1 (ko) * | 2016-04-26 | 2016-12-13 | 한국프라임제약주식회사 | 혈관내피성장인자 수용체 융합단백질 |
| JP7071994B2 (ja) * | 2017-03-30 | 2022-05-19 | プロガストリン、エ、カンセル、エス、アー エル、エル | 前立腺がんを治療するための組成物および方法 |
| WO2019028171A1 (en) * | 2017-08-01 | 2019-02-07 | Ptc Therapeutics, Inc. | DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS |
| WO2019083172A1 (ko) * | 2017-10-24 | 2019-05-02 | 국립암센터 | 스트렙토니그린 및 라파마이신을 유효성분으로 포함하는, 암 예방 또는 치료용 약학적 조성물 |
| CN116059318A (zh) | 2018-01-26 | 2023-05-05 | 加利福尼亚大学董事会 | 用于使用抗vegf剂治疗血管生成病症的方法和组合物 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| WO2020106049A1 (ko) * | 2018-11-20 | 2020-05-28 | (주)엠디바이오랩 | 스트렙토니그린 및 항암제를 모두 포함하는 암 예방 또는 치료에 사용하기 위한 약학적 조성 |
| KR20200094110A (ko) * | 2019-01-29 | 2020-08-06 | (주)엠디바이오랩 | 스트렙토니그린 및 항암제를 포함하는 뇌종양 예방 또는 치료용 조성물 |
| WO2020159171A2 (ko) * | 2019-02-01 | 2020-08-06 | (주)엠디바이오랩 | 스트렙토니그린 및 항암제를 포함하는 대장암 예방 또는 치료용 약학적 조성물 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| BR112022010113A2 (pt) | 2019-11-25 | 2022-09-06 | Univ California | Inibidores de vegf de longa ação para neovascularização intraocular |
| WO2021226444A2 (en) | 2020-05-08 | 2021-11-11 | Regeneron Pharmaceuticals, Inc. | Vegf traps and mini-traps and methods for treating ocular disorders and cancer |
| US20220196166A1 (en) * | 2020-12-18 | 2022-06-23 | Nibco Inc. | L-ball union drain valve |
| US11898643B1 (en) | 2022-12-28 | 2024-02-13 | Nibco Inc. | Dual union ball drain valve with T-flow adjustability |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US7264801B2 (en) * | 1998-08-11 | 2007-09-04 | Genentech, Inc. | EG-VEGF nucleic acids and polypeptides and method of use |
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| JP4723140B2 (ja) * | 1999-06-08 | 2011-07-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 改善された薬物動態特性を有する改変キメラポリペプチド |
| US6833349B2 (en) * | 1999-06-08 | 2004-12-21 | Regeneron Pharmaceuticals, Inc. | Methods of treating inflammatory skin diseases |
| AU2004242586C1 (en) * | 2003-05-28 | 2011-02-24 | Regeneron Pharmaceuticals, Inc. | Method of treating corneal transplant rejection by using VEGF antagonists |
| US7186699B2 (en) * | 2003-06-03 | 2007-03-06 | Cell Genesys, Inc. | Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes |
| CA2519875C (en) * | 2003-06-06 | 2014-01-14 | Regeneron Pharmaceuticals, Inc. | Method of tumor regression with vegf inhibitors |
-
2005
- 2005-06-10 MX MXPA06014421A patent/MXPA06014421A/es not_active Application Discontinuation
- 2005-06-10 EP EP12176929.3A patent/EP2583685A1/en not_active Withdrawn
- 2005-06-10 AU AU2005254058A patent/AU2005254058A1/en not_active Abandoned
- 2005-06-10 WO PCT/US2005/020762 patent/WO2005123104A2/en not_active Application Discontinuation
- 2005-06-10 JP JP2007527795A patent/JP2008502738A/ja not_active Withdrawn
- 2005-06-10 EP EP05750079A patent/EP1753442A2/en not_active Ceased
- 2005-06-10 CN CNA2005800189582A patent/CN101102786A/zh active Pending
- 2005-06-10 US US11/149,738 patent/US7354580B2/en active Active
- 2005-06-10 CA CA002567686A patent/CA2567686A1/en not_active Abandoned
-
2006
- 2006-11-23 IL IL179515A patent/IL179515A0/en unknown
-
2008
- 2008-02-29 US US12/072,965 patent/US7482001B2/en active Active
- 2008-02-29 US US12/072,967 patent/US7479272B2/en active Active
- 2008-02-29 US US12/074,104 patent/US7479274B2/en active Active
- 2008-02-29 US US12/074,096 patent/US7479273B2/en active Active
- 2008-02-29 US US12/074,140 patent/US7479275B2/en active Active
- 2008-02-29 US US12/072,966 patent/US7482002B2/en active Active
-
2011
- 2011-11-10 JP JP2011246211A patent/JP2012067116A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012067116A5 (US20070167479A1-20070719-C00034.png) | ||
| US20200281921A1 (en) | Cancer treatment with combination of plinabulin and taxane | |
| JP2008507536A5 (US20070167479A1-20070719-C00034.png) | ||
| ES2409755T3 (es) | Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado | |
| JP2007515469A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2011511072A5 (US20070167479A1-20070719-C00034.png) | ||
| US20190307723A1 (en) | Compositions and methods for intravenous administration of 2-bromo-1-(3,3-dinitroazetidin-1-yl)ethanone | |
| JP2008540364A5 (US20070167479A1-20070719-C00034.png) | ||
| US20100266590A1 (en) | Combination therapy | |
| CN114224889A (zh) | 西奥罗尼联合免疫检查点抑制剂在抗肿瘤治疗中的应用 | |
| WO2019072220A1 (zh) | Pd-1抗体和表观遗传调节剂联合在制备治疗肿瘤的药物中的用途 | |
| BR112015024621B1 (pt) | Usos de dose unitária de unidades formadoras de colônia de c. novyi e de dose unitária de esporos de c. novyi nt e kit para tratar ou atenuar um efeito de um tumor sólido presente em um ser humano | |
| JP2014523398A5 (US20070167479A1-20070719-C00034.png) | ||
| RU2015152860A (ru) | Режим введения и составы для аденовирусов типа в | |
| JP2011500805A5 (US20070167479A1-20070719-C00034.png) | ||
| KR20130085939A (ko) | 소세포 폐암의 치료 방법 | |
| TWI486172B (zh) | 鼻咽癌治療的醫藥 | |
| JP2015514796A (ja) | ２から３０ｍｇ／ｋｇの範囲の用量で癌を治療するのに使用するためのデキサナビノールまたはこの誘導体 | |
| JP2016520665A (ja) | Ｍｐｓ−１キナーゼ阻害剤および有糸分裂阻害剤を含む、癌の治療のための組合わせ | |
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| CN117442704A (zh) | 一种治疗前列腺癌的药物组合及其应用 | |
| JP2013540725A5 (US20070167479A1-20070719-C00034.png) | ||
| JP2016521760A (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| Papadopoulos et al. | A phase Ia study in patients with advanced solid tumors for the human monoclonal antibody vantictumab (OMP-18R5; anti-Frizzled) targeting the WNT pathway | |
| US11911374B2 (en) | Methods and uses for treating cancer |
